https://www.selleckchem.com/pr....oducts/gsk591-epz015
Transcriptomic analysis of PAK4-targeted tumors revealed inhibition of the RAS-GTPase, Hedgehog, and Notch pathways, along with evidence of activation of antitumor immune response signatures. This PAK4-targeting gene signature showed prognostic significance for patients with sarcoma. Overall, our results show for the first time that PAK4 is a novel and viable therapeutic target for the treatment of high-risk RMS. SIGNIFICANCE These data demonstrate a novel oncogenic role for PAK4 in rhabdomyosarcoma and show that tar
Like
Comment
Share
